^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vesencumab (MNRP1685A)

    i
    Other names: MNRP1685A, RG7347, R 7347, M 1685A
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    Neuropilin inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    A Comprehensive Analysis of NRP1 in Malignancies Provide Therapeutic Implication for Treating Cancer Patients Infected with SARS-CoV-2. (PubMed, Biochem Genet)
    Overall, NRP1 appears to play a critical role in regulating immunological properties and metabolism in many tumor types. Specific inhibitors of the NRP1 antigen (pegaptanib, EG00229, or MNRP1685A) combined with other anti-SARS-CoV-2 strategies may aid in treating patients with lung and genitourinary cancers following SARS-CoV-2 infection.
    Journal
    |
    NRP1 (Neuropilin 1)
    |
    vesencumab (MNRP1685A)
    almost4years
    Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation. (PubMed, Breast Cancer Res)
    These data implicate NRP1 in the aggressive phenotype of claudin-low breast cancer and offer a novel targeted therapeutic approach to this poor prognosis subtype.
    Journal • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • NRP1 (Neuropilin 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ITGA6 (Integrin, alpha 6)
    |
    ER negative • ZEB1 expression
    |
    vesencumab (MNRP1685A)